Synfacts 2022; 18(06): 0677
DOI: 10.1055/s-0041-1738364
Chemistry in Medicine and Biology

Targeted Protein Stabilization with DUBTACs

Contributor(s):
Dirk Trauner
,
Joseph A. Flores
Nomura DK. * et al. University of California, Novartis-Berkeley Center for Proteomics and Chemistry Technologies and Innovative Genomics Institute, Berkeley, USA
Deubiquitinase-Targeting Chimeras for Targeted Protein Stabilization.

Nat. Chem. Biol. 2022;
18: 412-421
DOI: 10.1038/s41589-022-00971-2.
 

Significance

Irregular protein degradation plays a critical role in the pathogenesis of many diseases, such as cystic fibrosis and several forms of cancer. Thus, targeted protein stabilization (TPS) offers a novel therapeutic strategy for such cases. Utilizing an approach analogous to proteolysis-targeting chimeras (PROTACs), Nomura and co-workers developed deubiquitinase-targeting chimeras (DUBTACs) as small-molecule recruiters of the deubiquitinase OTUB1 to stabilize polyubiquitinated proteins of interest tagged for proteasomal degradation.


#

Comment

Using chemoproteomics, Nomura and co-workers identified OTBU1 as an ideal candidate for recruitment and demonstrated acrylamide EN523 be a selective ligand for OTBU1 with no loss of activity. DUBTAC NJH-2-057 was generated by linking EN523 to the pharmaceutical drug lumacaftor to target mutant chloride channel ΔF508-CFTR, the degradation of which is associated with the cystic fibrosis phenotype. In vitro assays demonstrated a dose-dependent and time-responsive restoration of CFTR levels and function, justifying further investigations into DUBTAC-mediated TPS.


#
#

Publication History

Article published online:
17 May 2022

© 2022. Thieme. All rights reserved

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany